# Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

> **NCT04899908** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 134 (estimated)

## Conditions studied

- Brain Cancer
- Brain Metastases
- Melanoma
- Lung Cancer
- Breast Cancer
- HER2-positive Breast Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- SRS
- SRT
- Whole Brain Radiation
- Stereotactic Radiation
- AGuIX
- Nanoparticle
- Cystic
- Brain Tumor

## Interventions

- **RADIATION:** Stereotactic Radiation
- **DRUG:** AGuIX gadolinium-based nanoparticles
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04899908
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2028-04
- **Final completion:** 2029-05
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899908, "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04899908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*